Boehringer Ingelheim

April 12, 2016April 12, 2016

European Union Approves Giotrif (Afatinib) for Lung Squamous Cell Carcinoma

Lung Cancer, News

The European Union (EU) approved Giotrif (afatinib) on April 8 for the treatment of advanced squamous cell carcinoma (SqCC) of the lung in people for whom the disease has progressed despite treatment ... Read more

April 11, 2016April 11, 2016

Just 20% of COPD Patients May See Benefit from Inhaled Corticosteroids, Study Finds

COPD, News

Boehringer Ingelheim recently announced that a new study showed that the levels of specific white blood cells (eosinophils) can help to identify patients with chronic obstructive pulmonary disease (COPD) who ... Read more

March 28, 2016March 28, 2016

Boehringer Ingelheim Enrolls 1st Patient in ‘Real World’ Study of Pradaxa for Deep Vein Thrombosis and PE

News, Pulmonary embolism

Boehringer Ingelheim pharmaceutical company recently announced the launch and enrollment of the first patient in its RE-COVERY DVT/PE global observational study, which will eventually include 14,000 patients globally and collect data on ... Read more

March 4, 2016March 16, 2016

IPF Patient Survey Reveals Fear, Worry Most Commonly Experienced Emotions When Diagnosed

Idiopathic Pulmonary Fibrosis, News

An international online survey with more than 500 participants suffering from idiopathic pulmonary fibrosis (IPF) provided a picture into the real-life emotions of these patients. The survey was conducted by Germany-based Boehringer Ingelheim ... Read more

February 29, 2016May 13, 2016

Ofev (Nintedanib) Slows IPF Disease Progression, According to Analysis of Studies

Idiopathic Pulmonary Fibrosis, News

An analysis of the Phase II TOMORROW trial and two Phase III INPULSIS trials (INPULSIS-1 and INPULSIS-2), analyzing the safety and efficacy outcomes for Ofev (nintedanib, developed by Boehringer Ingelheim), revealed that ... Read more

February 25, 2016March 16, 2016

‘Breathless’ Campaign, to Raise Awareness of IPF, Launched by Musician Joe Nichols and Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals and country music artist Joe Nichols are launching a national education campaign called Breathless aimed at raising awareness for idiopathic pulmonary fibrosis (IPF), its symptoms, and the importance of ... Read more

February 10, 2016February 10, 2016

Lung Function in COPD Patients Shows Promise With STIOLTO RESPIMAT Inhalation Spray

COPD, News

Boehringer Ingelheim Pharmaceuticals announced the publication of promising new data regarding its inhalation spray, STIOLTO RESPIMAT, in the improvement of lung function when compared to therapy with an European formulation combining ... Read more

February 5, 2016May 13, 2016

New Inhaled Asthma Treatment, SPIRIVA RESPIMAT, Now Available in U.S.

Asthma, COPD, News

Boehringer Ingelheim Pharmaceuticals recently announced that SPIRIVA RESPIMAT, a new inhaled medicine for maintenance treatment of asthma, is now available by prescription in U.S. pharmacies for adults and adolescents. The U.S. Food ... Read more

January 29, 2016February 3, 2016

British Health Institute Recommends OFEV for Adults with IPF

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced that the British National Institute for Health and Care Excellence (NICE) has recommended OFEV (nintedanib) as a therapy for adult patients with idiopathic pulmonary fibrosis (IPF) within the National ... Read more

December 15, 2015December 15, 2015

New IPF Study to Test OFEV/Esbriet as Combination Therapy

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim announced that it has initiated a 12-week clinical trial investigating the safety, tolerability, and pharmacokinetics of pirfenidone (marketed as Esbriet by Genentech) as an add-on to treatment with OFEV (nintedanib). The ... Read more